Roswell Park Faculty to Present at National Comprehensive Cancer Network 2026 Annual Conference - Report - MDSpire

Roswell Park Faculty to Present at National Comprehensive Cancer Network 2026 Annual Conference

Clinical researchers from Roswell Park Comprehensive Cancer Center are among the experts invited to share insights and clinical best practices at the National Comprehensive Cancer Network (NCCN) 2026 Annual Conference March 27-29 in Orlando, Florida.

  • By

  • March 26, 2026

  • 3 min

Share

Clinical Report: Roswell Park Faculty to Present at NCCN 2026 Annual Conference

Overview

{'add': 'Include specific dates of the conference.'}

Background

The National Comprehensive Cancer Network (NCCN) Annual Conference serves as a critical platform for oncology professionals to share advancements in cancer treatment and care. Presentations from leading researchers can influence clinical practices and improve patient outcomes. The involvement of Roswell Park faculty highlights their commitment to advancing cancer care through research and collaboration.

Data Highlights

{'clarify': 'Mention the absence of numerical data but suggest including qualitative insights.'}

Key Findings

{'verify': 'Cross-check all presenters and topics against the source material.'}

Clinical Implications

{'expand': 'Detail specific impacts on clinical practices or patient outcomes.'}

Conclusion

{'enhance': "Emphasize the conference's role in ongoing research and future clinical practices."}

References

  1. Roswell Park Comprehensive Cancer Center, Join Roswell Park at AACR 2026
  2. Roswell Park Comprehensive Cancer Center, Insights on Sarcomas, Gastroesophageal Cancers, Peritoneal Tumors Anchor Roswell Park Presentations at SSO 2026
  3. The ASCO Post, NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
  4. FDA Approves T-DXd With Pertuzumab for First-Line Treatment of Advanced HER2+ Breast Cancer | Pharmacy Times
  5. Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM
  6. The ASCO Post — 2015-2016 Oncology Meetings
  7. FDA Approves T-DXd With Pertuzumab for First-Line Treatment of Advanced HER2+ Breast Cancer | Pharmacy Times
  8. Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM - Roswell Park Comprehensive Cancer Center
  9. FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies | FDA

Original Source(s)

Roswell Park Faculty to Present at National Comprehensive Cancer Network 2026 Annual Conference

  • by

  • March 26, 2026

Related Content

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026